The Technical Analyst
Cancer Genetics Inc [VYNT]
Exchange: Nasdaq Capital Market Sector: Healthcare Industry: Biotechnology
Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-4.65% $1.230
Last updated: 21 Jan 2022 @ 11:35 am
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 35.66 mill |
| EPS: | -1.150 |
| P/E: | 0.000 |
| Earnings Date: | Nov 11, 2021 |
| SharesOutstanding: | 28.99 mill |
| Avg Daily Volume: | 0.136 mill |
| RATING 2022-01-20 |
|---|
| B+ |
| Buy |
| RATING DETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.39 (94.54%) $1.163 |
| Date: 2022-01-21 |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-01-18 | Fletcher R John | Buy | 3 721 | Common Stock, $0.0001 par value |
| 2022-01-18 | Horobin Joanna | Buy | 5 343 | Common Stock, $0.0001 par value |
| 2022-01-18 | Harris Geoffrey E. | Buy | 4 055 | Common Stock, $0.0001 par value |
| 2022-01-18 | Hansen Paul R. | Buy | 2 862 | Common Stock, $0.0001 par value |
| 2022-01-18 | Boehm Marcus | Buy | 5 725 | Common Stock, $0.0001 par value |
| INSIDER POWER |
|---|
| 92.76 |
| Last 100 transactions |
| Buy: 9 653 668 | Sell: 192 572 |
Forecast:
13:12 - $1.250
Live Trading Signals (every 1 min)
Forecast 1: 11:42 - $1.235
Forecast 2: 12:32 - $1.242
Forecast 3: 13:12 - $1.250
SCORE
-8.50
Sell
-8.50
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Last version updated: Wed 15th Dec 2021
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.230 (-4.65% ) |
| Volume | 0.0197 mill |
| Avg. Vol. | 0.136 mill |
| % of Avg. Vol | 14.43 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VYNT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
| Date | Signal | @ | Closed | % | Jan 21 - 16:24 | sell | $1.234 | N/A | Active |
|---|
VYNT
Latest Press Releases
2021-08-19 09:27:00 - Press Release
Vyant Bio And Cyclica Announce A Strategic Collaboration To Identify Compounds To Treat Cdkl5 Deficiency Disorder
Cherry hill, nj and toronto, canada, aug. 19, 2021 (globe newswire) -- vyant bio, inc., (nasdaq: vynt), a leading biotech company discovering new therapeutics for neurological diseases and hard-to-treat cancers, and cyclica, inc., the partner of choice for data driven drug discovery, today announced a non-exclusive strategic collaboration combining vyant bio's patient-derived complex organoid biology alongside cyclica's proteome-wide, artificial intelligence (“ai”) enabled discovery platform to identify new treatments for cdkl5 deficiency disorder (“cdd”), a severe neurodevelopmental epilepsy disorder with no effective treatments or cure.
2021-08-11 09:00:00 - Press Release
Vyant Bio Announces Investor Conference Call And Webcast For second Quarter 2021
Cherry hill, n.j., aug. 11, 2021 (globe newswire) -- vyant bio, inc. (“vyant bio”, “company”) (nasdaq: vynt), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (cns) and oncology-related diseases. with leading-edge capabilities in data science, biological and chemical sciences, engineering, and regulatory affairs, vyant bio capitalizes on in silico, human cell-derived in vitro disease models, and in vivo discovery technologies to identify novel biological targets and valuable therapeutics for patients. today, vyant bio announced that an investor conference call and webcast will be hosted on monday, august 16, 2021.
2021-07-13 08:20:00 - Press Release
Vyant Bio Announces Issuance Of Key Patent For High-throughput Optical Assay Of Human Mixed Cell Population Spheroids
Cherry hill, n.j., july 13, 2021 (globe newswire) -- vyant bio, inc. (“vyant bio”, the “company”) (nasdaq: vynt), an emerging leader in novel drug discovery technologies, announced today that its wholly-owned subsidiary, stemonix, inc. (“stemonix”), was issued us patent no. 11054408, titled “high throughput optical assay of human mixed cell population spheroids” by the united states patent and trademark office (uspto).
2021-05-17 17:15:00 - Press Release
Vyant Bio Reports First Quarter 2021 Results And Provides Strategic Business Update
Cherry hill, n.j., may 17, 2021 (globe newswire) -- vyant bio, inc. (the “company”) (nasdaq: vynt), is an innovative biotechnology company focused on partnering with pharmaceutical and other biotechnology companies to identify novel and repurposed therapeutics through the integration of human-derived biology with data science technologies and ind-enabling expertise.
2021-05-11 16:36:00 - Press Release
Vyant Bio To Present At Bionj's 11th Annual Biopartnering Conference
Cherry hill, n.j., may 11, 2021 (globe newswire) -- vyant bio, inc. (“vyant bio”, “company”) (nasdaq: vynt), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of therapeutics for biopharma partners as well as for the proprietary pipeline of the company.
Latest News
2021-11-29 09:15:00 - GlobeNewsWire
Vyant Bio to Present at The Benchmark Company Discovery One-on-One Investor Conference
Cherry Hill, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that it will be participating in The Benchmark Company Discovery One-on-One Investor Conference. The event is being held virtually on Thursday, December 2, 2021.
2021-11-15 14:50:06 - Seeking Alpha
Vyant Bio's (VYNT) CEO Jay Roberts on Q3 2021 Results - Earnings Call Transcript
2021-11-11 16:49:43 - Proactive Investors
Vyant Bio reports total revenue of $1.5M in 3Q 2021, shares strategic updates
Vyant Bio (NASDAQ:VYNT) Inc announced its third-quarter 2021 strategic and business updates, reporting total revenue of $1.5 million for the three months ending September 30, 2021, compared to $1.9 million in 3Q 2021. During the quarter, the New Jersey-based company announced that it appointed Robert Fremeau as the new chief scientific officer, who will be lead Vyant Bio (NASDAQ:VYNT)'s research and development programs.
2021-11-10 16:15:00 - GlobeNewsWire
Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference
Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that it will be presenting at the Q4 Investor Summit Micro & Small Cap Conference (“Q4 Investor Summit”). The event is being held virtually from November 16-17, 2021.
2021-11-09 09:15:00 - GlobeNewsWire
Vyant Bio Announces Investor Conference Call and Webcast for the Third Quarter 2021
CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio , Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Thursday, November 11, 2021.
2021-10-26 09:44:52 - Proactive Investors
Vyant Bio appoints Robert Fremeau as chief scientific officer
Vyant Bio Inc has announced the appointment of Robert Fremeau as the company's new chief scientific officer. Vyant said Fremeau is an experienced research and development leader with over two decades of drug discovery experience in academia and industry, advancing next-generation drug development for severe neurological disorders.
2021-10-19 10:07:33 - Proactive Investors
Vyant Bio forges partnership with MASORI Therapeutics to pursue co-development partnerships with pharma companies
Vyant Bio Inc. has announced a new partnership with MASORI Therapeutics, a company focused on the pharmaceutical industry and applying artificial intelligence to achieve competitive advantage through the creation of innovative market solutions.
2021-10-11 07:36:43 - Proactive Investors
HC Wainwright initiates coverage on Vyant Bio with 'Buy' recommendation and $5 price target
2021-08-19 11:53:52 - Proactive Investors
Vyant Bio and Cyclica in a strategic collaboration to identify compounds to treat CDKL5 Deficiency Disorder
Vyant Bio Inc, a biotech company discovering new therapeutics for neurological diseases and hard-to-treat cancers, and Cyclica Inc, announced a non-exclusive strategic collaboration combining Vyant Bio's patient-derived complex organoid biology alongside Cyclica's proteome-wide, Artificial Intelligence (AI) enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder (CDD), a severe neurodevelopmental epilepsy disorder with no effective treatments or cure. Cherry Hill, New Jersey-based Vyant's human-first approach to novel drug discovery incorporates patient biology into the earliest steps of the process with highly functional, disease-based neural organoids; while Cyclica's proprietary machine learning platforms marry knowledge and structure-based approaches to find novel targets, uncover new uses for existing drugs, and design new molecules with high potential.
2021-08-19 09:27:00 - GlobeNewsWire
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
CHERRY HILL, NJ and TORONTO, CANADA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc., (Nasdaq: VYNT), a leading biotech company discovering new therapeutics for neurological diseases and hard-to-treat cancers, and Cyclica, Inc., the partner of choice for data driven drug discovery, today announced a non-exclusive strategic collaboration combining Vyant Bio's patient-derived complex organoid biology alongside Cyclica's proteome-wide, Artificial Intelligence (“AI”) enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder (“CDD”), a severe neurodevelopmental epilepsy disorder with no effective treatments or cure.